Terns Pharmaceuticals (TERN)
(Delayed Data from NSDQ)
$7.46 USD
-0.31 (-3.99%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $7.46 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Terns Pharmaceuticals, Inc. (TERN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$14.21 | $22.00 | $5.50 | 82.88% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Terns Pharmaceuticals, Inc. comes to $14.21. The forecasts range from a low of $5.50 to a high of $22.00. The average price target represents an increase of 82.88% from the last closing price of $7.77.
Analyst Price Targets (7 )
Broker Rating
Terns Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.44 a month ago based on nine recommendations.
Of the eight recommendations deriving the current ABR, six are Strong Buy, representing 75% of all recommendations. A month ago, Strong Buy represented 77.78%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/TERN.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 7 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.44 | 1.44 | 1.44 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/30/2024 | JMP Securities | Silvan C Tuerkcan | Strong Buy | Strong Buy |
4/17/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Strong Buy |
3/27/2024 | UBS | Eliana Merle | Strong Buy | Strong Buy |
3/15/2024 | BMO Capital Markets | Etzer Darout | Strong Buy | Strong Buy |
3/15/2024 | H.C. Wainwright & Co. | Ed Arce | Hold | Hold |
12/1/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 8 |
Average Target Price | $14.21 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 88 of 253 |
Current Quarter EPS Est: | -0.35 |